COMPANY PROFILE

Invuity

A medical technology company focused on pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during open minimally invasive and minimal…

San Francisco, United StatesFounded 2004Health Tech & Medtech

Valuation $0–100M Latest valuation · 2015

Revenue $10–50M Latest reported FY

Total funding $100–500M Disclosed equity funding

About Invuity

Invuity, Inc. operated as a medical technology company, establishing a notable presence in the advanced surgical devices market before its acquisition. Founded in 2004 by Alex Vayser and headquartered in San Francisco, California, the firm focused on enhancing surgical procedures through superior visualization. The company's core offering was its patented Intelligent Photonics technology, a sophisticated system designed to illuminate surgical cavities during minimally invasive operations. This technology utilized proprietary optical waveguides to provide broad, uniform, and thermally cool light, enabling surgeons to work with greater precision, safety, and efficiency, particularly in deep and dark surgical sites.

Read full description

The business model centered on the development and sale of single-use, lighted surgical instruments. Its product portfolio included a variety of retractors, handheld devices, and drop-in illuminators. These tools were applied across a wide range of clinical specialties, including orthopedic and spine surgery, gynecology, breast cancer and reconstructive surgery, thyroid procedures, and general surgery. The company's clients were primarily hospitals and surgeons who perceived the products as differentiated, allowing Invuity to command premium pricing. The firm went public in June 2015 and had raised a total of $99.1 million in funding over several rounds from investors such as HealthCare Royalty Partners, Wellington, and Valence Life Sciences.

A significant milestone in the company's history was its acquisition by Stryker Corporation. The definitive agreement was announced in September 2018, with Stryker acquiring all outstanding shares of Invuity for approximately $190 million. The acquisition was completed in October 2018, after which Invuity became a wholly-owned subsidiary of Stryker and its shares were delisted from NASDAQ. The move was seen as highly complementary to Stryker's instruments business, combining its leadership in minimal access surgery with Invuity's visualization technology to improve patient outcomes and operating room efficiencies.

Source: Dealroom company data